PBS Biotech Secures $22 Million to Expand Single-Use Manufacturing Solutions for Cell Therapy Clients

PBS Biotech, a leading provider of innovative biomanufacturing solutions, has successfully raised $22 million in funding to expand its single-use manufacturing products and services tailored for the growing cell therapy market. The investment will enable PBS Biotech to accelerate its offerings to clients in the cell therapy sector, supporting the ongoing demand for efficient and scalable manufacturing processes in the production of cell-based therapies.

The funding round was led by prominent investors who see the potential for significant growth in the cell therapy industry, which has been rapidly expanding in recent years. The increased focus on regenerative medicine, immunotherapy, and personalized medicine has created an urgent need for advanced manufacturing solutions that can support the large-scale production of cell therapies while maintaining stringent quality control and cost-efficiency. PBS Biotech’s single-use bioreactors and associated technologies are well-positioned to meet these demands, making the company a key player in the cell therapy manufacturing landscape.

“We are excited to have secured this funding, which will allow us to expand our capabilities and better serve the needs of our cell therapy clients,” said Dr. Karen I. Pugh, CEO of PBS Biotech. “The cell therapy industry is at a pivotal point, with innovations in treatments like CAR-T and stem cell therapies showing great promise. However, scaling production to meet patient demand requires reliable, cost-effective, and flexible manufacturing solutions. With this investment, we will be able to enhance our product offerings and support the next generation of life-changing therapies.”

PBS Biotech specializes in single-use bioreactors, which provide a flexible, cost-effective, and scalable solution for the production of biologics, including cell therapies. Unlike traditional stainless-steel bioreactors, which require extensive cleaning and validation between uses, single-use systems eliminate the need for time-consuming cleaning processes, reducing the risk of contamination and improving overall production efficiency. This is especially important in the field of cell therapy, where production volumes are often smaller and highly specialized, but the quality and consistency of the product are critical for patient safety.

The $22 million investment will be used to enhance PBS Biotech’s product development, expand its manufacturing capacity, and increase its R&D efforts to address the evolving needs of the cell therapy sector. The company plans to introduce new single-use manufacturing solutions that can accommodate a wider range of cell types and production processes, offering more flexibility and customization to clients. Additionally, the funds will support the growth of PBS Biotech’s engineering team and the expansion of its customer support infrastructure, enabling the company to provide more comprehensive services to its growing client base.

The cell therapy market has seen rapid growth in recent years, driven by advancements in gene therapies, immunotherapies, and regenerative medicine. However, one of the primary challenges faced by companies in this field is scaling up production to meet the increasing demand for these therapies. PBS Biotech’s solutions offer a way to overcome this hurdle by providing a more efficient and scalable approach to biomanufacturing, allowing cell therapy developers to meet production demands without compromising on quality or patient safety.

“This investment is a testament to the growing need for innovative manufacturing solutions in the cell therapy space,” said Mark Thomas, Partner at one of the lead investors in PBS Biotech’s funding round. “PBS Biotech’s single-use bioreactor technology has the potential to transform the way cell therapies are produced, enabling companies to bring their treatments to market faster and more cost-effectively. We are excited to support PBS Biotech as they continue to innovate and expand their impact on the industry.”

As the cell therapy sector continues to mature, the demand for specialized manufacturing solutions is expected to rise. PBS Biotech is well-positioned to capitalize on this trend, offering state-of-the-art technologies that can scale with the industry’s growth. With this new round of funding, PBS Biotech is set to expand its market reach and play an instrumental role in supporting the commercialization of cutting-edge cell therapies.

In addition to enhancing its product offerings, PBS Biotech also plans to invest in expanding its strategic partnerships with key players in the cell therapy ecosystem, including research institutions, pharmaceutical companies, and contract development and manufacturing organizations (CDMOs). These partnerships will help the company strengthen its position in the market and ensure that its solutions continue to meet the evolving needs of the industry.

The $22 million funding round underscores the growing confidence in PBS Biotech’s ability to drive innovation in the biomanufacturing space and further solidifies its role as a leader in single-use manufacturing solutions. As the cell therapy industry continues to grow, PBS Biotech is poised to be a critical enabler of the next generation of life-saving therapies, helping to bring these treatments to market faster and more efficiently.